May 2026: Focused on internal code quality and build hygiene to reduce release risk and improve maintenance for hmftools. Delivered data-model simplification (PurityPloidyFit), manifest accuracy improvements, and naming cleanup for FindingStatus. These changes reduce build brittleness, improve packaging reliability, and create a cleaner foundation for future features in the Hartwig hmftools repo.

April 2026 monthly summary for hartwigmedical/hmftools. Delivered end-to-end improvements to findings processing, with robust error handling, refined status reporting, and enhanced germline handling; advanced status logic for predictions and PTO to align with OncoAct; expanded conversion utilities and data-model improvements; and broad core refactoring for maintainability and extensibility. Result: more reliable clinical reporting, reduced manual intervention, and a stronger foundation for future analytics and OncoAct integration.

March 2026 performance highlights for hartwigmedical/hmftools: standardized thresholds and findings configuration, substantial data model refactor and naming alignment, broader low-purity coverage across PTO/HLA, and improved reliability of findings visibility through a FindingStatus overhaul. These changes improve data integrity, inclusivity of small variants under low purity, and maintainability, with traceable commits across modules.

2026-01 Monthly summary for hartwigmedical/hmftools: Key features delivered, major bugs fixed, and business impact. Key features delivered: - Data model refactor and API evolution enabling forward-compatibility (GainDeletion interface, chromosomeArmCopies API, and metadata properties). - LOH/HRD gene list enhancements with LOHCopyNumbers and a genes list method returning MSI or HRD genes. - IO utilities for FindingRecords: read/write JSON and conversion from Orange JSON to findings, including versioning for FindingRecord. - Todo feature with creation and updates, plus tests. - Codebase cleanup and maintainability improvements (deterministic sorting of findings, improved exception messaging). Major bugs fixed: - NIO compatibility issue restored correct IO behavior. - Pharmaco contamination handling to mark unreliable data. - Duplication removal and code formatting maintenance. - Additional refactors to improve reliability and readability. Overall impact and accomplishments: - Stronger data integrity, easier data interchange, and improved developer productivity; reduced time to deploy new features; higher confidence in production behavior. Technologies/skills demonstrated: - Python code refactoring, API design, JSON IO (read/write, conversion), test coverage, data modeling, deterministic sorting, error handling, and adherence to formatting standards.

December 2025: Delivered core genomic findings data model enhancements in hmftools and completed a broad codebase cleanup with module dependency refactor. The changes strengthen genomic analysis capabilities, reduce maintenance burden, and improve deployment stability.

November 2025 monthly summary for hartwigmedical/actin focused on delivering robust clinical-trials data capabilities, improving runtime reliability, and modernizing I/O to support scalable workflows. Key work includes a new data model for actionable items in trials, a robust TrailProvider that gracefully handles empty ACTIN trial sets, and a migration to NIO-based file I/O for better performance and maintainability. These changes enhance filtering, evidence management, and trial data orchestration while reducing edge-case failures and enabling smoother future integrations.

Performance highlights for 2025-08: Delivered an API extension enabling OncoACTIN to utilize external trial data through an optional external-trials set in the TrialsProvider, while preserving existing default behavior. Implemented an explicit fix for OncoPanel version identification by pinning the panel version to a specific date, ensuring accurate data extraction in targeted experiments. These changes enhance data completeness and reliability for external data integrations and experimental analyses. Technical work emphasized backward-compatible API design, conditional data flows, and robust versioning strategies, laying groundwork for smoother onboarding of external data sources and more dependable downstream analytics.

July 2025 (2025-07) monthly summary for hartwigmedical/actin: Delivered a feature to customize the report date in the Reporter Application, enabling fixed dates via a command-line argument for report generation. This enhances reproducibility, auditability, and automation readiness of reporting workflows. The work is tracked under ACTIN-2184 (#1224) and committed as 3b4770f2a56b5e3c7fcee44151daf5c15ea6f01a. No major bugs fixed this month in this scope. Technologies demonstrated include CLI argument parsing, maintainable code design, and strong change traceability.

June 2025 summary for hartwigmedical/actin: Delivered unfiltered retrieval of external clinical trials by refactoring TrialsProvider to support unfiltered access while preserving existing filtering paths. Updated and expanded the test suite to validate new behavior and regression coverage. No major bugs fixed this month; focus was on feature delivery and test coverage to enable broader data access and downstream analytics.

May 2025 (hartwigmedical/actin): Delivered core feature work across testing utilities, data modeling, and reporting to strengthen test stability, data integrity, and maintainability. Key business value includes more reliable Java-friendly test utilities, a robust treatment data model with a default to drug class, and a streamlined trial reporting pipeline that reduces complexity and onboarding time for data consumers.

April 2025: Delivered molecular evidence data model enhancements and trial data integration for hartwigmedical/actin. Extended the trial data model with new fields and refined structures to better represent trial information and molecular evidence. Added new evidence types, improved extraction/representation of molecular evidence, and performed refactoring and bug fixes to ensure data integrity and consistency. Simplified data by removing redundant flags and standardizing URL fields to improve reliability and maintainability. These changes enable more accurate analytics, easier integration of future trial data, and a more maintainable data platform.

March 2025 performance summary for hartwigmedical/actin focusing on delivering reusable trial interpretation capabilities and improved reporting fidelity. Key outcomes include: OncoACT Trial Interpretation Module — refactor to reusable module and introduced the TrialsProvider class to encapsulate trial presentation and interpretation; added Source field to ExternalTrialSummary for provenance tracking. PDF rendering upgrade — upgraded iText to 1.9.0 with updated API and corrected bold/italic styling in generated reports. Business value: reduced duplication, faster onboarding for new trials, improved provenance and auditability, and more reliable client reports. Technologies/skills demonstrated: modular design, provider pattern, API evolution, dependency upgrade (iText), and robust report generation.